The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON1) activity

Journal of Physiology and Pharmacology

Volumn 53, Issue 3, 2002, Pages 463-475

  Bełtowski, Jerzy ^a   Wojcicka G ^a   Mydlarczyk, M ^a   Jamroz, A ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Fenofibrate; Lipid peroxidation; Oxidative stress; Paraoxonase; Peroxisome proliferator activated receptors

Indexed keywords

ALDEHYDE DERIVATIVE; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; FENOFIBRATE; FERRIC ION; LIPID HYDROPEROXIDE; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; HYDROLYSIS; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; RAT STRAIN; REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; ARYLDIALKYLPHOSPHATASE; ESTERASES; LIPID PEROXIDATION; LIPIDS; MALE; OXIDATIVE STRESS; PROCETOFEN; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036739584     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-925.
2. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109.
3. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
4. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998; 81: 912-917.
5. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-853.
6. Frick MH, Syvanne M, Nieminen MS et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96: 2137-2143.
7. Ruotolo G, Ericsson CG, Tettamanti C et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32: 1648-1656.
8. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
9. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118.
10. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety in treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
11. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-651.
12. Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA. Longterm mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991; 266: 1225-1229.
13. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 39-44.
14. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherogenesis. FASEB J 2001; 15: 2073-2084.
15. Vazquez M, Merlos M, Adzet T, Laguna JC. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. Br J Pharmacol 1996; 117: 1155-1162.
16. Arnaiz SL, Travacio M, Monserrat AJ, Cutrin JC, Llesuy S, Boveris A. Chemiluminescence and antioxidant levels during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1997; 1360: 222-228.
17. Inoue I, Noji S, Awata T et al. Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver. Life Sci 1998; 63: 135-144.
18. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-280.
19. Yoshida H, Ishikawa T, Ayaori M, Shige H, Ito T, Suzukawa M, Nakamura H. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. Atherosclerosis 1998; 139: 179-187.
20. Chaput E, Maubrou-Sanchez D, Bellamy FD, Edgar AD. Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol. Lipids 1999; 34: 497-502.
21. Evans M, Anderson RA, Graham J et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 101: 1773-1779.
22. Bredie SJ, de Bruin TW, Demacker PN, Kastelein JJ, Stalenhoef AF. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995; 75: 348-353.
23. Grodzińska L, Jachym R, Slawiński M, Robak J. influence of bezafibrate on total antioxidant activity of serum and deformability of blood cells in hypercholesterolaemic patients. Pol J Pharmacol 1998; 50: 361-364.
24. O'Neal DN, O'Brien RC, Timmins KL et al. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabet Med 1998; 15: 870-877.
25. Becuwe P, Bianchi A, Keller JM, Dauca M. Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line. Biochem Pharmacol 1999; 58: 1025-1033.
26. Ciriolo MR, Rossi L, Mavelli I et al. The effects of hypolipidemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liver. Arzneimittelforschung 1984; 34: 465-467.
27. Arnaiz SL, Travacio M, Llesuy S, Boveris A. Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Biochim Biophys Acta 1995; 1272: 175-180.
28. Scatena R, Nocca G, De Sole P, Fresu R, Zuppi C, Giardina B. The priming effect of gemfibrozil on reactive oxygen metabolism of phagocytic leucocytes. An intriguing side effect. Clin Chim Acta 1997; 266: 173-183.
29. de Man FH, Jonkers IJ, Schwedhelm E et al. Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy. Arterioscler Thromb Vasc Biol 2000; 20: 2434-2440.
30. Rose ML, Rusyn I, Bojes HK, Belyea J, Cattley RC, Thurman RG. Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat Res 2000; 448: 179-192.
31. Melchiorri D, Reiter RJ, Attia AM, Hara M., Burgos A, Nistico D. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci 1995; 56: 83-89.
32. Naurooz-Zadeh J, Tajaddini-Sarmadi J, Wolf SP. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjuction with triphenylphosphine. Anal Biochem 1994; 220: 403-409.
33. Benzie IFF, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP Assay. Anal Biochem 1996; 239: 70-76.
34. Cao G, Prior RL: Comparison of different analytical methods for assesing total antioxidant capacity of human serum. Clin Chem 1998; 44: 1309-1315.
35. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du B: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its function. A possible peroxidative role of paraoxonase. J Clin Invest 1998; 101: 1581-1590.
36. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99: 62-66.
37. Ayub A, Mackness MI, Sharon A, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335.
38. Mancini FP, Lanni A, Sabatino L et al. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 2001; 491: 154-158.
39. Klucis E, Crane D, Masters C. Et al. Sequential alterations in the micro-localization of catalase in mouse liver after treatment with hypolipidemic drugs. Mol Cell Biochem 1984; 65: 73-82.
40. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-32841.
41. Delerive P, De Bosscher K, Besnard S et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048-32054.
42. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 1980; 20: 560-564.
43. de la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 1999; 66: 166-172.
44. Xu X, Otsuki M, Saito H et al. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology 2001; 142: 3332-3339.
45. Staels B, Koenig W, Habib A et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-793.
46. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-3131.
47. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalphaleukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
48. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE: Free radicals and phagocytic cells. FASEB J 1995; 9: 200-209.
49. Bae JH, Bassenge E, Lee HJ et al. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis 2001; 158: 165-171.
50. Gueraud F, Alary J, Costet P et al. In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARalpha-deficient mice. J Lipid Res 1999; 40: 152-159.
51. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Bio. 2001; 21: 473-480.
52. Durrington PN, Mackness MI, Bhatnagar D et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138: 217-225.